2019 American Transplant Congress » Poster Session B: Kidney Immunosuppression: Desensitization

6:00pm-7:00pm

5-Year Post-Transplant Outcomes with Bortezomib-Based Desensitization in Renal Transplant Recipients

K. Zheng¹, S. Tremblay¹, A. R. Shields², M. A. Cardi², J. Kremer², R. R. Alloway¹, E. S. Woodle¹

6:00pm-7:00pm

Blood Group Incompatible Living Donor Kidney Transplantation in Patients with End-Stage Kidney Disease Due to Diabetes Kidney Disease

J. Uchida¹, A. Kosoku¹, K. Kabei¹, S. Nishide¹, H. Shimada¹, K. Maeda², Y. Yoshikawa³, T. Iwai¹, N. Kuwabara¹, T. Naganuma¹, N. Kumada⁴, Y. Takemoto¹, T. Nakatani¹

6:00pm-7:00pm

Costs Associated with A2 to B Kidney Transplantation: A Barrier to Its Utilization?

R. Forbes, B. Concepcion, D. Shaffer

6:00pm-7:00pm

Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?

J. O. Paixão, L. R. Ulisses, P. S. Souza, G. Bezerra, F. Agena, H. P. Rodrgues, N. Panajotopoulos, F. J. Paula, E. David-Neto, M. R. Castro

6:00pm-7:00pm

Desensitization Using Only Polyvalent Immunoglobulins (IVIG) for Kidney Transplantation with Living Donors (LD)

L. R. Ulisses, J. O. Paixão, P. S. Souza, G. Bezerra, H. Rodrigues, N. Panajatopoulos, F. J. De Paula, E. David-Neto, M. C. R Castro

6:00pm-7:00pm

Detection and Desensitization of Donor-Specific Antibody Reduces Risk of Early but Not Late Renal Transplant Failure in a Cohort of 1000 Cases

M. Tsai, C. Lee, C. Yang, C. Chen

6:00pm-7:00pm

Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.

D. J. Sindi¹, A. Al Jedai², H. Aleid³, J. Brockmann⁴, M. Al-Awwami⁵, D. Alissa², E. De Vol⁶, H. Al Khabbaz⁷, L. Fajji⁸

6:00pm-7:00pm

Hepatitis Flare in Hepatitis B Core Antibody Positive Kidney Recipients Treated with Rituximab

M. Raja¹, Y. Natori¹, C. Donato¹, D. De Lima¹, J. Rivollo², A. Centeno², Y. Ebisu¹, L. Abbo¹, J. Simkins¹, S. Anjan¹, J. Camargo¹, M. I. Morris¹

6:00pm-7:00pm

Outcomes in Preformed Donor-Specific Human Leukocyte Antibody Positive Living Kidney Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab

Y. kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹

6:00pm-7:00pm

Overcoming Anti-HLA Sensitization in Kidney Transplantation

R. C. Siqueira¹, P. Malafronte², J. C. Baptista-Silva², E. F. Silva², M. C. Camargo², M. C. Ribeiro Castro²

6:00pm-7:00pm

Reduction of Circulating DSA: Does It Affect Histology?

M. Gupta¹, E. Edusei¹, S. Tsai², M. Magruder², J. Lee¹, J. Lee¹, C. Hartono¹, T. Muthukumar¹, M. Everly³, D. Dadhania¹

6:00pm-7:00pm

Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients

R. F. Parsons¹, S. Bumb², H. Decker¹, A. Zahid¹, C. Sullivan¹, T. Pearson¹, C. Larsen¹, M. Levine³, M. Kamoun³, R. A. Bray¹, H. M. Gebel¹

6:00pm-7:00pm

Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAi Kidney Transplantation

A. A. Vo, E. Huang, S. Williamsons, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, S. C. Jordan

6:00pm-7:00pm

Successful Use of Nonantigen Specific Immunoadsorption In ABO-Incompatible Desensitization and Humoral Rejection Treatment in Kidney Transplantation

E. Montagud-Marrahi

6:00pm-7:00pm

“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA

A. Casillas-Abundis, A. Tambur, A. Shetty, C. D'Agostino, J. R. Leventhal